Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Ocular Therapeutix ( (OCUL) ).
Effective January 20, 2026, Ocular Therapeutix, Inc. announced that Chief Financial Officer and Chief Operating Officer Donald Notman has taken a temporary medical leave of absence. On the same date, the board appointed Jason Robins, previously Senior Vice President of Finance, as interim Chief Financial Officer and as the company’s principal financial and accounting officer, granting him a stock option for 33,000 shares vesting over four years under the company’s 2021 Stock Incentive Plan. Robins, 49, joined Ocular Therapeutix in January 2025 after serving as Vice President of Finance at Fusion Pharmaceuticals Inc., and his appointment involves no related-party transactions or special arrangements with other company insiders, signaling a routine, internally sourced leadership transition with standard indemnification protections during Notman’s absence.
The most recent analyst rating on (OCUL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ocular Therapeutix stock, see the OCUL Stock Forecast page.
Spark’s Take on OCUL Stock
According to Spark, TipRanks’ AI Analyst, OCUL is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, negative operating cash flow, and declining revenue) and bearish technicals (below key moving averages with negative MACD). These are partly offset by a relatively strong earnings-call outlook driven by clinical-trial progress and stated funding runway, while valuation provides limited support due to negative earnings and no dividend yield.
To see Spark’s full report on OCUL stock, click here.
More about Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing therapies, with operations that require dedicated oversight of accounting, reporting, financial planning and analysis, and corporate planning functions to support its growth and regulatory obligations.
Average Trading Volume: 3,620,217
Technical Sentiment Signal: Buy
Current Market Cap: $2.44B
See more insights into OCUL stock on TipRanks’ Stock Analysis page.